<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531920</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-E044-030</org_study_id>
    <nct_id>NCT01531920</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel</brief_title>
  <official_title>A Phase 1 Study in Healthy Subjects to Determine the Safety, Tolerability, Psychomotor Function and Cognitive Effects of Perampanel When Administered With Alcohol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 study in healthy subjects to determine the safety, tolerability, psychomotor
      function, and cognitive effects of perampanel when administered alone and with alcohol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Changes on Psychomotor Performance (Continuous Tracking Test [CTT]), due to perampanel and alcohol combined and perampanel alone</measure>
    <time_frame>baseline to Part A Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Changes on Psychomotor Performance (Continuous Tracking Test [CTT]) due to perampanel and alcohol combined and perampanel alone</measure>
    <time_frame>baseline to Part B Day 62</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B:Changes in Cognitive Function due to perampanel and alcohol combined and perampanel alone</measure>
    <time_frame>baseline to Part B Day 62</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Part B: Changes in driving performance (simulated) due to perampanel and alcohol combined and perampanel alone</measure>
    <time_frame>Part B Day 34</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Incidence of AEs when perampanel is administered in combination with alcohol</measure>
    <time_frame>baseline to Part A Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Incidence of AEs when perampanel is administered in combination with alcohol</measure>
    <time_frame>baseline to Part B Day 62</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Central Nervous System</condition>
  <arm_group>
    <arm_group_label>alcohol + placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part A alcohol + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alcohol + perampanel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part A : alcohol + perampanel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>perampanel + alcohol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part B: perampanel + alcohol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo + alcohol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part B: placebo + alcohol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alcohol + placebo</intervention_name>
    <description>Part A alcohol + placebo</description>
    <arm_group_label>alcohol + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alcohol + perampanel</intervention_name>
    <description>Part A: alcohol + perampanel</description>
    <arm_group_label>alcohol + perampanel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perampanel + alcohol</intervention_name>
    <description>Part B: perampanel + alcohol</description>
    <arm_group_label>perampanel + alcohol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo + alcohol</intervention_name>
    <description>Part B: placebo + alcohol</description>
    <arm_group_label>placebo + alcohol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Healthy male and female subjects

          -  Females agreed to use two medically acceptable methods of contraception, unless they
             were surgically sterile

          -  Aged 18-55 yrs, inclusive

          -  Achieved a Continuous Tracking Test (CTT )score increase of &gt;1.5 pixels from
             pre-alcohol when dosed with alcohol during the Screening Period (Day minus 8
             plus/minus 2 days)

          -  Had a current driving license and drove regularly (e.g., more than 1000 miles a year
             (Part B only)

        Exclusion:

          -  Any history of significant alcohol abuse or psychiatric disease, requiring inpatient
             admission or prolonged treatment with psychotropic medication

          -  Unable to follow the instructions for the psychometric testing

          -  Intolerant to the driving simulator (Part B only)

          -  Unable to adhere to long periods of confinement (subjects who could not follow the
             instructions of the protocol, including the meals)

          -  Use of prescription drugs or over-the-counter (OTC) medications within 2 weeks prior
             to Screening (unless drug had a long half life [i.e., 5 x t 1/2&gt;2 weeks]) with the
             exception of paracetamol (up to 4 g/day), which was allowed up to 12 hours prior to
             dosing

          -  Had taken any inhibitor of CYP450 within 2 weeks prior to the first dosing (e.g.,
             grapefruit, grapefruit juice, grapefruit-containing beverages, or Seville orange
             products)

          -  Had taken St John's Wort or other dietary aids known to induce CYP3A4 within 4 weeks
             prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daryl Bendel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Surrey Clinical Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2012</study_first_posted>
  <last_update_submitted>February 10, 2012</last_update_submitted>
  <last_update_submitted_qc>February 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

